MARAVAI LIFESCIENCES HOLDINGS INC
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
MRVI$7.86-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except per share amounts)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenue | $288,945 | $883,001 | $799,240 |
| Operating expenses: | |||
| Cost of revenue | 148,743 | 168,957 | 140,561 |
| Selling, general and administrative | 151,390 | 129,259 | 100,064 |
| Research and development | 17,280 | 18,369 | 15,219 |
| Change in estimated fair value of contingent consideration | (3,286) | (7,800) | — |
| Restructuring | 6,466 | — | — |
| Gain on sale of business | — | — | (11,249) |
| Total operating expenses | 320,593 | 308,785 | 244,595 |
| (Loss) income from operations | (31,648) | 574,216 | 554,645 |
| Other income (expense): | |||
| Interest expense | (45,892) | (20,414) | (30,260) |
| Interest income | 27,727 | 2,338 | — |
| Loss on extinguishment of debt | — | (208) | — |
| Change in payable to related parties pursuant to the Tax Receivable Agreement | 668,886 | (4,102) | 6,101 |
| Other (expense) income | (1,337) | (358) | 279 |
| Income before income taxes | 617,736 | 551,472 | 530,765 |
| Income tax expense | 756,111 | 60,809 | 61,515 |
| Net (loss) income | (138,375) | 490,663 | 469,250 |
| Net (loss) income attributable to non-controlling interests | (19,346) | 270,458 | 287,213 |
| Net (loss) income attributable to Maravai LifeSciences Holdings, Inc. | $(119,029) | $220,205 | $182,037 |
| Net (loss) income per Class A common share attributable to Maravai LifeSciences Holdings, Inc.: | |||
| Basic | $(0.90) | $1.67 | $1.59 |
| Diluted | $(0.90) | $1.67 | $1.56 |
| Weighted average number of Class A common shares outstanding: | |||
| Basic | 131,919 | 131,545 | 114,791 |
| Diluted | 131,919 | 255,323 | 257,803 |
The accompanying notes are an integral part of these consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.